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Background: Local renal ischemia is regarded as an important factor in the development of contrast-induced
nephropathy (CIN). Mannose-binding lectin (MBL) is involved in the tissue damage during experimental ischemia/
reperfusion injury of the kidneys. The aim of the present study was to investigate the association of MBL deficiency
with radiocontrast-induced renal dysfunction in a large prospective cohort.
Methods: 246 patients with advanced non–dialysis-dependent renal dysfunction who underwent radiographic
contrast procedures were included in the study. Baseline serum MBL levels were analyzed according to the
occurrence of a creatinine-based (increase of ≥0.5 mg/dL or ≥25% within 48 hours) or cystatin C-based (increase of
≥10% within 24 hours) CIN.
Results: The incidence of creatinine-based and cystatin C-based CIN was 6.5% and 24%, respectively. MBL levels
were not associated with the occurrence of creatinine-based CIN. However, patients that experienced a cystatin C
increase of ≥10% showed significantly higher MBL levels than patients with a rise of <10% (median 2885
(IQR 1193–4471) vs. 1997 (IQR 439–3504)ng/mL, p = 0.01). In logistic regression analysis MBL deficiency (MBL
levels≤500 ng/ml) was identified as an inverse predictor of a cystatin C increase ≥10% (OR 0.34, 95% CI 0.15-0.8,
p = 0.01).
Conclusion: MBL deficiency was associated with a reduced radiocontrast-induced renal dysfunction as reflected
by the course of cystatin C. Our findings support a possible role of MBL in the pathogenesis of CIN.
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Acute kidney injuryBackground
Contrast-induced nephropathy (CIN) is the third leading
cause of acute renal failure in hospitalized patients as a
result of the expanded use of iodinated contrast media
(CM). Consequently, this iatrogenic complication is
associated with prolonged hospitalization, significant
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reproduction in any medium, provided the or[1,2]. The incidence of CIN is higher in patients with
predisposing risk factors such as renal impairment, dia-
betes mellitus, advanced age, congestive heart failure,
simultaneous use of nephrotoxic drugs, hypovolemia or
large amounts of CM [3].
The pathophysiology of CIN is complex and not fully
understood. Yet, evidence from numerous studies sug-
gests that a combination of several mechanisms is
responsible for the development of CIN [4]. Local renal
ischemia is a direct result of CM induced prolonged
vasoconstriction, which primarily affects the outer
medulla. Hypoxic injury to this region is aggravated byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tration of CM. Consequently, oxidative stress, which
enhances the production of reactive oxygen species
(ROS) and triggers a local inflammatory response, may
cause additional cell injuries during the reperfusion
phase [5]. The second important effect of CM involves
direct cytotoxic damage to renal tubular cells.
Mannose-binding lectin (MBL) is an innate pattern-
recognition, multimeric protein of the complement sys-
tem that is primarily synthesized in the liver. Several
mutations in the MBL2 gene negatively influence the
concentration of circulating functional MBL multimers.
Hence, MBL deficiency can be observed in up to 30% of
the Caucasian population [6]. Binding of MBL to certain
sugar residues on pathogens leads to the activation of
the lectin pathway of the complement cascade and sub-
sequently to killing or phagocytosis of microorganisms.
Furthermore, MBL is also involved in the binding and
removal of dying cells, e.g. after ischemic injury [7,8].
With regard to ischemia and oxidative stress several
studies have highlighted the crucial role of MBL in
aggravating the inflammatory response and tissue
damage during ischemia/reperfusion (I/R) injury of
the heart [9-11], the brain [12,13], as well as the kidney
[14-16]. However, comparable data in human CIN are
scarce. In a recent study Wang et al. have shown that
MBL was strongly upregulated in the urine proteome
profiles after application of CM [17]. Moreover, in patients
with CIN urine levels of MBL significantly increased after
the procedure whereas MBL levels remained stable in
patients who did not develop CIN. These results suggest
that the lectin pathway might be involved in the pathogen-
esis of human contrast-medium-induced kidney injury.
Hence, the current study tested the hypothesis that MBL
deficiency is associated with a reduced incidence of CIN.
Methods
Study design
Post-hoc analysis of a multicenter, randomized, open-
label, controlled trial (Clinicaltrials.gov Identifier:
NCT00130598) that compared three different prevention
procedures of CIN between March 2005 and December
2009 [18]. The primary endpoint of the study was the
maximum change in estimated glomerular filtration rate
(eGFR) within 48 hours.
Study population
In the original trial 273 admitted patients with renal dys-
function, who were scheduled to receive radiographic
CM during diagnostic or therapeutic procedures within
the next 24 hours, were randomized to three prevention
regimens. Subsequently, 258 patients were included in
the final analysis. The study was conducted according to
the principles of the revised Declaration of Helsinki, hadbeen approved by the local ethical committees (Ethikkom-
mission beider Basel, Basel/Liestal, Switzerland; Comitato
Etico Centro Cardiologico Monzino, Milano, Italy), and
all participants gave written informed consent for the
study. The aim of the original trial was to investigate two
regimens of sodium bicarbonate vs. standard volume
supplementation with isotonic sodium chloride in the
prevention of CIN.
Renal dysfunction was defined as serum creatinine
level >93 μmol/L for women and >117 μmol/L for men
or eGFR <60 mL/min/1.73 m2 as assessed 24 hours
before the radiographic procedure. Patients were excluded
if they were <18 years old, pregnant, or allergic to radio-
graphic contrast, were undergoing dialysis, had severe
heart failure (NYHA III-IV), had taken N-acetylcysteine
≤24 hours before CM administration, or had a clinical
vulnerable condition requiring continuous fluid therapy
(e.g. severe sepsis).
Patients were randomly assigned to one of three pre-
ventive regimens which are outlined in more detail in
the original study [18] (Group A: Standard 24 h sodium
chloride; group B: 7 h sodium bicarbonate; group C:
Short-term sodium bicarbonate).
Definition of endpoints
The primary endpoint for this study was the develop-
ment of CIN. Multiple definitions have been used to
quantify renal damage after CM. Creatinine-based CIN
was defined as an increase of ≥44 μmol/L or ≥25%
in serum creatinine concentration within 48 hours after
exposure to CM. Cystatin C is an evolving marker for
the prediction and diagnosis of CIN. Several studies sug-
gest that serum cystatin C is a more sensitive and rapid
indicator of changes in GFR than serum creatinine [19].
In a recent study, a cystatin C increase of ≥10% 24 hours
after exposure to CM was found to reliably predict the
occurrence of CIN and future adverse events (death
from any cause and chronic dialysis) [20]. Therefore,
we included this cut-off for the definition of cystatin-
based CIN in our secondary analysis. Serial serum
cystatin C samples were available from 241 of 258
patients. Furthermore, time to hospital discharge, in-
hospital morbidity and mortality, renal replacement
therapy and mortality at 90 days were included as sec-
ondary endpoints.
Assessment of renal function
Peripheral venous blood samples for the measurement
of creatinine and cystatin C were obtained on the day
preceding the scheduled administration of CM and in
the morning of the subsequent two days after the con-
trast exposure. The measurement of these parameters is
outlined in more detail in the original study [18].
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viate Modification of Diet in Renal Disease (MDRD)
equation [21].
Determination of mannose-binding lectin levels
For the MBL level analysis baseline serum samples were
available from 246 of 258 patients. MBL serum con-
centrations were measured on the same day blinded to any
patient data using a commercially available Sandwich-
ELISA Kit (MBL Oligomer ELISA KIT 029, Lucerna Chem,
Luzern, Switzerland) as described previously [22].
Depending on the clinical setting several cut-off values
for MBL deficiency have been proposed ranging from 100
to 1000 ng/mL [6]. Thus, we first analyzed the predefined
endpoints in relation to MBL levels, and only in a second-
ary analysis chose a threshold of ≤500 ng/mL for the def-
inition of MBL deficiency, as this cut-off has been shown
to reliably predict low-producing MBL2 genotypes [23].
Statistical analysis
Continuous data are expressed as means (standard devi-
ation) or median (interquartile range (IQR)) where appro-
priate, whereas categorical variables are summarized as
frequency (percentage). Differences in patient characteris-
tics and outcome measures according to MBL serostatus
were analyzed using the Fisher`s exact test or the
Mann–Whitney-U-Test where appropriate. Due to the
non-Gaussian distribution of human MBL levels (as
determined by Q-Q plot and normality tests) two-group
comparison of serum MBL levels were performed using a
Mann–Whitney-U-test, whereas a Kruskal-Wallis one-way
analysis of variance or Friedman test was used for multi-
group comparison where appropriate. Dunn’s post test
was used to correct p-values for multiple comparisons.
Stepwise logistic regression models were used to estimate
the effect of MBL levels on predefined endpoints in multi-
variate analyses after adjustment for covariables with uni-
variate P values less than 0.1. Covariables tested in
univariate analysis included patient age, sex, baseline renal
function (as assessed by serum creatinine or cystatin C),
history of vascular risk factors, acute myocardial infarction
or congestive heart failure, amount of administered CM,
medication use, prevention regimen (B or C versus A) and
baseline blood pressure. All testing was two-tailed, and p
values less than 0.05 were considered to be statistically sig-
nificant. All statistical analyses were performed with the use
of SPSS for Windows, version 15.0 (SPSS), and Prism for
Windows, version 4 (GraphPad).
Results
Patients’ characteristics and mannose-binding lectin
serum levels
The analyzed study cohort consisted of 246 elderly
patients (mean age 75 years) with renal dysfunction whounderwent intravenous or intraarterial contrast proce-
dures. Median eGFR at baseline was 44 (IQR 35–52)
mL/min/1.73 m2. The majority of patients underwent
either computer tomography (45%) or cardiac cathe-
terization with or without PCI (21 and 24%, respect-
ively), and 100 (IQR 80–160) mL of CM was
administered on average during contrast procedures.
The median MBL serum level was 2150 (IQR 560–3794)
ng/mL, and 57 of 246 (23%) individuals showed levels
≤500 ng/mL. Similar MBL concentrations were observed
in the three intervention groups and in patients with a
baseline eGFR of <30, 30–59, and ≥60 ml/min/1.73 m2
(data not shown). Important clinical characteristics of
the whole study cohort and classified according to the
chosen threshold for the definition of MBL deficiency
are summarized in Table 1. With the exception of pre-
procedural diastolic blood pressure and use of non-
steroidal anti-inflammatory drugs patients with MBL
levels ≤500 ng/mL did not differ significantly from
patients with MBL levels >500 ng/mL with regard to
baseline characteristics.
Mannose-binding lectin and creatinin-based contrast-
induced nephropathy
The incidence of CIN, defined as a maximum increase
in serum creatinine concentration of more than
44 μmol/L or 25% within 48 hours after exposure to
CM, was 6.5% (16/246) in the whole study cohort. In
individuals with CIN median serum creatinine levels
rose from 140 μmol/L (IQR 103–164) at baseline to
170 μmol/L (110–202) and 202 μmol/L (125–266) at
24 and 48 hours, respectively (p = 0.02 for baseline vs.
48 hours), whereas cystatin C levels had already
increased significantly from 2.06 mg/L (IQR 1.38-2.48)
at baseline to 2.65 mg/L (1.77-3.10) at 24 hours (p =
0.038). MBL levels in patients who experienced an acute
deterioration of renal function did not differ significantly
from patients that showed stable creatinine concentra-
tions (median 2603 (IQR 519–3988) vs. 2126 (563–
3794) ng/mL, p = 0.6, Figure 1). Results were similar
when each intervention group was analyzed separately
(data not shown).
With respect to the predefined MBL cut-off 3/57
(5.3%) patients with MBL deficiency developed CIN
within 48 hours as compared to 13/189 (6.9%) patients
with MBL levels >500 ng/mL (p = 1.0).
Mannose-binding lectin and cystatin C-based contrast-
induced nephropathy
Recently, an increase of cystatin C ≥10% after exposure
to CM was identified as an independent marker for the
development of CIN or future adverse events [20]. In
our study population serum cystatin C levels rose ≥10%
in 58/241 (24%) individuals after undergoing contrast
Table 1 Clinical characteristics of patients
Baseline characteristics All MBL ≤500 ng/mL MBL >500 ng/mL P-value
(n = 246) (n = 57) (n = 189)
Age in years, mean (SD) 75 (9.4) 74 (10.5) 75 (9.5) 0.4
Female sex, n (%) 89 (36) 24 (42) 65 (34) 0.4
MBL in ng/mL, median (IQR) 2150 (560–3794) 127 (11–330) 2855 (1701–4347) n/a
BMI in kg/m2, median (IQR) 26 (23–29) 27 (24–30) 26 (23–29) 0.09
Contrast medium in mL, median (IQR) 100 (80–160) 100 (80–150) 100 (80–170) 0.3
Medical history
Hypertension, n (%) 204 (83) 48 (84) 156 (83) 0.8
D.m., n (%) 90 (37) 19 (33) 71 (38) 0.6
Dyslipidemia, n (%) 145 (59) 34 (60) 111 (59) 1.00
Coronary heart disease, n (%) 143 (58) 31 (54) 112 (59) 0.5
CHF, n (%) 111 (45) 23 (40) 88 (47) 0.5
Peripheral artery disease, n (%) 64 (26) 11(19) 53 (28) 0.2
Current smoking, n (%) 40 (16) 7 (12) 33 (17) 0.4
Medication
ACE-Inhibitor, n (%) 108 (44) 23 (40) 85 (45) 0.7
AT-II-Inhibitor, n (%) 69 (28) 13 (23) 56 (30) 0.40
Diuretics, n (%) 173 (70) 41 (72) 132 (70) 0.9
NSAIDs, n (%) 8 (3) 5 (9) 3 (2) 0.02
Baseline parameters
Systolic BP in mmHg, median (IQR) 130 (120–146) 132 (120–149) 130 (117–145) 0.1
Diastolic BP in mmHg, median (IQR) 70 (60–80) 76 (65–80) 70 (60–80) 0.01
Creatinine in μmol/L, median (IQR) 137 (114–162) 140 (113–154) 136 (114–164) 0.9
Cystatin C in mg/L, median (IQR) 1.7 (1.5-2.0) 1.8 (1.5-2.0) 1.7 (1.5-2.1) 0.8
eGFR in mL/min/1.73 m2, median (IQR) 44 (35–52) 44 (35–51) 44 (35–53) 0.8
Type of procedure
Coronary angiogram, n (%) 110 (45) 23 (40) 87 (46) 0.5
PCI, n (%) 52 (21) 12 (21) 40 (21) 1.00
CT scan, n (%) 110 (45) 29 (51) 81 (43) 0.3
Other, n (%) 26 (11) 5 (9) 21 (11) 0.8
Intervention group
Standard 24 h sodium chloride, n (%) 85 (35) 16 (28) 69 (37) 0.3
7 h sodium bicarbonate, n (%) 82 (33) 22 (39) 60 (32) 0.3
Short-term sodium bicarbonate, n (%) 79 (32) 19 (33) 60 (32) 0.9
P-values are given for the difference between MBL ≤500 and >500 ng/ml. Abbreviations: D.m. = Diabetes mellitus; IQR = interquartile range; BMI = body mass
index; CHF = congestive heart failure class I/II by New York Heart Association classification; NSAIDs = non-steroidal anti-inflammatory drugs; eGFR = estimated
glomerular filtration rate; CT scan = computer tomography scan. PCI = percutaneous coronary intervention; BP = blood pressure; SD = standard deviation.
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levels did not change significantly from baseline
(132 μmol/L (IQR 112–150)) to 24 hours (133 μmol/L
(IQR 111–170)) and 48 hours after exposure to CM
(141 μmol/L (IQR 113–187); p = 0.54), and 13 of these
58 individuals simultaneously met the definition of
creatinine-based CIN as mentioned above. Serum MBL
levels were significantly higher in patients with an in-
crease of serum cystatin C ≥10% compared to patientswith a rise of <10% (median 2885 (IQR 1193–4471) vs.
1997 (IQR 439–3504) ng/mL, p = 0.01) (Figure 2). This
association could be observed to a similar extent in each
of the three intervention groups reaching statistical
significance in group A and C (data not shown). Fur-
thermore, 50/185 (27%) MBL sufficient patients, i.e.
>500 ng/mL, developed a cystatin C increase of ≥10%
after the contrast procedure compared to only 8/56
(14%) patients with MBL deficiency (p = 0.05).
Figure 1 Differences in MBL serum concentrations according
to the occurrence of creatinine-based CIN (defined as increase
in serum creatinine concentration of ≥44 μmol/L or 25%
within 48h). Horizontal lines represent medians.
Table 2 Independent predictors of a cystatin C increase
>10% after exposure to CM
Variable OR 95% CI P-value
MBL deficient phenotype (<500 ng/ml) 0.34 0.15-0.80 0.01
Prevention regimen
Standard 24 h sodium chloride 1
7 h sodium bicarbonate 3.40 1.52-7.60 0.003
Short-term sodium bicarbonate 2.93 1.28-6.70 0.01
Baseline diastolic blood pressure1 1.03 1.00-1.05 0.054
Variables entered into the stepwise logistic regression analysis were age, sex,
baseline cystatin C, history of vascular risk factors, acute myocardial infarction,
congestive heart failure, amount of administered contrast medium, medication
use, prevention regimen and baseline blood pressure.
1 per mmHg.
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cient phenotype (i.e. <500 ng/mL) remained associated
with a reduced risk of a cystatin C increase of ≥10% (OR
0.34 (95% CI 0.15-0.80), p = 0.01, Table 2). In addition,
higher MBL levels were identified as risk factor for a
cystatin C increase >10% when MBL levels were entered
as continuous variable into the analysis (OR 1.32 (95%
CI 1.10-1.58) for every 1000 ng/mL increase, p = 0.003).Figure 2 Differences in MBL serum concentrations according to
the occurrence of a serum cystatin C increase ≥10% after
exposure to contrast media. Horizontal lines represent medians.Mannose-binding lectin and clinical outcomes
Follow-up was completed in all patients included in this
analysis. In-hospital morbidity and mortality, dialysis
dependency and mortality at 3 months did not differ sig-
nificantly between MBL deficient and sufficient indivi-
duals (Table 3). There was a non significant trend
towards a longer hospital stay in MBL sufficient indivi-
duals. In addition, median MBL levels were significantly
higher in patients who were readmitted for cardiac
reasons within 3 months after administration of CM
(median 3059 (IQR 1392–4218) vs. 1899 (IQR 467–
3727), p = 0.03), whereas there was no difference in
MBL levels with regard to in-hospital morbidity and
mortality, dialysis dependency and mortality at 3 months
(data not shown).
Discussion
The lectin pathway of the complement system has been
shown to considerably contribute to tissue damage dur-
ing ischemia/reperfusion injury of several organs, includ-
ing the kidneys [14,16]. This is the first study to assess
the importance of serum MBL with respect to the devel-
opment of CIN in a clinical trial. MBL deficiency did not
influence the occurrence of CIN as defined by a com-
monly quoted serum creatinine increment. However,Table 3 Clinical outcomes dependent on MBL serotype






Length of stay in days,
median (IQR)
6 (3–13) 8 (3–16) 0.07
In-hospital morbidity
and mortality, n (%)
4 (7) 6 (3) 0.25
Dialysis dependency
at 3 months, n (%)
2 (4) 2 (1) 0.23
Hospitalization for cardiac
cause at 3 months, n (%)
5 (9) 34 (18) 0.10
Mortality at 3 months,
n (%)
8 (14) 18 (10) 0.33
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after the administration of CM.
To our knowledge the role of MBL has not been inves-
tigated in a rodent model of CIN. However, the fact that
local ischemia and reperfusion is at least in part respon-
sible for the development of CIN [4], and that MBL
aggravates tissue damage during I/R injury [9,11,12,15],
suggests a role of MBL in the pathogenesis of contrast-
induced acute kidney injury.
With regard to the primary endpoint, the incidence of
creatinine-based CIN, several reasons might account for
the absent effect of MBL deficiency in this study.
According to the baseline characteristics, the study
cohort included only a rather small percentage of very
high-risk patients (as reflected by 29/246 (11.7%) with
GFR <30 mL/min/1.73 m2, 52/246 (21.1%) with coronary
angiography and ad hoc PCI, 69/246 (28.0%) with con-
trast media volume ≥140 mL [24], 90/246 (36.6%) with
diabetes mellitus, and the exclusion of patients with
advanced congestive heart failure), and CIN was diag-
nosed infrequently, especially in the sodium chloride
prevention group (incidence 1.2%). Due to the latter fact
the analysis of smaller differences between MBL
sufficient and deficient patients is limited. Furthermore,
in this study cohort low to moderate CM-induced
damage is probably not reflected by a decline in kidney
function as measured by the serum creatinine concen-
tration, a parameter with limited sensitivity to detect an
acute deterioration in renal function within 48 hours
[25]. Besides underestimating the true change in GFR,
the increase in serum creatinine after CM exposure is
delayed achieving a maximum two to five days after CM
exposure as compared to cystatin C, a more sensitive
marker, which was shown to rise earlier, to peak as early
as 24 hours after CM administration, and to detect even
subtle changes in GFR after acute kidney injury includ-
ing CIN [19,26-30]. Indeed, when we analyzed the influ-
ence of MBL deficiency on the cystatin C course after
CM exposure we observed a remarkable association: As
compared to patients with MBL levels >500 ng/mL
subjects with MBL deficiency were almost two-times less
likely to develop a cystatin C increase ≥10% after admin-
istration of CM, a cut-off that has recently been pro-
posed as an independent diagnostic and prognostic tool
with respect to the occurrence of CIN and future
adverse events [20]. This suggests that deficiency of
MBL might attenuate some of the detrimental effects of
CM. Though being small in magnitude this increase in
cystatin C of ≥10% might have important consequences
for the patients as even apparently minor decreases in
renal function have been shown to be associated with
excessive mortality rates independent of other known
risk factors [20,31]. However, we were not able to dem-
onstrate a consistent association of MBL deficiency withsuperior clinical outcomes, which the study was not
powered for.
On the other hand, the importance of renal I/R injury
in pathogenesis of CIN might be overestimated as
several other factors (including direct toxic effect on
renal tubular cells, increased urinary viscosity, and tubu-
lar obstruction) influence kidney function after exposure
to CM [32]. Moreover, I/R models that demonstrated
a pivotal role of MBL in the context of renal ischemia
(i.e. transient or permanent occlusion of a major renal
artery) are most likely not comparable to the complex
events occurring after administration of CM. The dur-
ation and extent of ischemia might be crucial as well.
In a rodent model of renal I/R activation of the MBL-
pathway was not induced by warm ischemia of less than
30 minutes [14]. Data on the duration and significance
of renal vasoconstriction and hypoxia after CM exposure
in humans remain controversial [4]. However, it has been
demonstrated that MBL and its associated protease
mannose-binding protein-associated serine protease 2
are strongly upregulated in the post-procedural urinary
proteome profiles after application of CM, and that urine
levels of MBL significantly increase in patients who
developed CIN whereas MBL levels remain stable in
non-CIN patients [17]. Finally, the alternative pathway
has been implicated in experimental renal ischemia/
reperfusion injury and might play a dominant role in
humans as compared to the MBL pathway [33].
Despite the randomized controlled trial design of the
original study and the precisely characterized cohort the
present study has important limitations including the
post hoc analysis of MBL serum levels and the use of a
surrogate marker as primary endpoint. Furthermore, lim-
iting the measurement of serum creatinine to 48 hours
after CM exposure might result in an underestimation of
creatinine-based CIN. As genetic material was not avail-
able, analysis of MBL deficiency solely relied on MBL
phenotype. However, MBL serum levels show little vari-
ation throughout life, and correlate well with the func-
tional activity of the MBL pathway in vivo [34]. As
individuals with the same genotype may vary up to ten-
fold in MBL serum levels, measurement of MBL serum
levels by ELISA might in fact represent a more reliable
approach than determination of genotypes [35,36]. MBL
levels (as measured by sandwich ELISA) have been
shown to be significantly increased in Asian pre-dialysis
and dialysis patients compared to healthy controls
[37,38]. To the best of our knowledge comparable stud-
ies in a Caucasian population with moderate renal
impairment (similar to our study patients) are lacking.
Conclusion
MBL deficiency did not influence the development of CIN
in this study cohort as defined by the course of serum
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radiocontrast-induced renal dysfunction as assessed by
cystatin C, a more sensitive and reliable parameter for esti-
mating GFR early after CM exposure. Additional studies
in patients at high risk for CIN are needed to fully eluci-
date the role of MBL in the pathogenesis of human CIN.
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